IRISS received 501 c-6 designation from Internal Revenue Service (IRS) on March 7, 2012. The 501 c-6 designation recognizes IRISS Forum as a pharmaceutical industry trade organization, which provides a mechanism for IRISS to collaborate with other trade organizations within the pharmaceutical industry (ie PhRMA, DIA, RAPS, HL7) as well as global Health Authorities. IRISS represents a neutral forum for industry, vendors, health authorities, consultants, etc. to share information and work towards a standard method of implementing electronic submission specifications and improving interoperability of e-publishing tools, viewing tools, and systems.

IRISS Forum operates through a directorship structure, governed by an executive committee and board of directors.


IRISS Operating Policy – August 2018
History of IRISS – February 2019

Board of Directors:

  • Co-chairs
    • Karen Towns
    • Jake Doran
  • Hans van Bruggen
  • David Berglund
  • Joakim Hindemith

Executive Committee:

  • President / CEO: Kelly Hnat
  • Vice President: Pending
  • Treasurer: open

Steering Committee:

  • Chair: Kelly Hnat (K2 Consulting)
  • Topic Groups:
    • AdPromo: Doug Kent (Janssen – J&J Pharma)
    • China Regional: Jannie Ren (Pfizer)
    • CMC: Marie Parrish (Sun Pharma Advanced Research Company)
    • Digitalization in Regulatory: Cesar Vinces (Pfizer)
    • Electonic Product Information: Tris Nockles
    • GSO: David Ross (AstraZeneca)
    • IDMP (XEVMPD): Frits Stulp (Iperion)
  • Website Liaison: Lenore Palma (Pharmaceutical eConsulting)
  • Communications Team: Kelly Hnat

Page last updated: 20 May 2020


Support the IRISS Forum by becoming a corporate sponsor. Several sponsorship levels are available. Please send an email to [email protected].